2003•Journal of the American College of CardiologyOpen access

First demonstration in humans of systemic neutral endopeptidase and endothelin converting enzyme inhibition using a new orally active dual metalloprotease inhibitor SLV 306

Alison Seed, Rhoda E. Kuc, Anthony P. Davenport, Michael Ashby, Chris Hillier, Hanka de Voogd, Hans Essers, John J.V. McMurray

Open full text 2 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

OpenAlex reports 2 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Neprilysin, Medicine, Orally active, Pharmacology, Enzyme, Metalloproteinase, Enzyme inhibitor, Biochemistry

Back to paper search Browse research topics Original source

First demonstration in humans of systemic neutral endopeptidase and endothelin converting enzyme inhibition using a new orally active dual metalloprotease inhibitor SLV 306 — Research Paper | ScholarLens